Bypass mechanisms of the androgen receptor pathway in therapy-resistant prostate cancer cell models.
about
Splice Variants of Androgen Receptor and Prostate CancerExpression and functional role of orphan receptor GPR158 in prostate cancer growth and progressionEmbryonal Fyn-associated substrate (EFS) and CASS4: The lesser-known CAS protein family membersCotargeting HSP90 and Its Client Proteins for Treatment of Prostate Cancer.AR variant ARv567es induces carcinogenesis in a novel transgenic mouse model of prostate cancer.Annotating STEAP1 regulation in prostate cancer with 89Zr immuno-PETModulation of androgen receptor signaling in hormonal therapy-resistant prostate cancer cell linesProteomic-coupled-network analysis of T877A-androgen receptor interactomes can predict clinical prostate cancer outcomes between White (non-Hispanic) and African-American groupsManagement of prostate cancer in port harcourt, Nigeria: changing patterns.MED1 mediates androgen receptor splice variant induced gene expression in the absence of ligandMK591, a second generation leukotriene biosynthesis inhibitor, prevents invasion and induces apoptosis in the bone-invading C4-2B human prostate cancer cells: implications for the treatment of castration-resistant, bone-metastatic prostate cancer.A novel nuclear role for the Vav3 nucleotide exchange factor in androgen receptor coactivation in prostate cancerA transductionally retargeted adenoviral vector for virotherapy of Her2/neu-expressing prostate cancer.Castration-resistant prostate cancer: mechanisms, targets, and treatment.AMBRA1 and SQSTM1 expression pattern in prostate cancer.Novel interaction between the co-chaperone Cdc37 and Rho GTPase exchange factor Vav3 promotes androgen receptor activity and prostate cancer growth.Overexpression of miR-499-5p inhibits non-small cell lung cancer proliferation and metastasis by targeting VAV3.Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches.Cancer and the metastatic substrate.Targeting metastatic castration-resistant prostate cancer: mechanisms of progression and novel early therapeutic approaches.Kallikrein-related peptidases targeted therapies in prostate cancer: perspectives and challenges.Wedelolactone, an Anti-inflammatory Botanical, Interrupts c-Myc Oncogenic Signaling and Synergizes with Enzalutamide to Induce Apoptosis in Prostate Cancer Cells.Dose-Dependent Therapeutic Distinction between Active and Passive Targeting Revealed Using Transferrin-Coated PGMA Nanoparticles.DNA Methylation and the HOXC6 Paradox in Prostate Cancer.A unifying biology of sex steroid-induced apoptosis in prostate and breast cancers.Implications of Bcl-2 and its interplay with other molecules and signaling pathways in prostate cancer progression.The Addition of Manganese Porphyrins during Radiation Inhibits Prostate Cancer Growth and Simultaneously Protects Normal Prostate Tissue from Radiation Damage.Testosterone Diminishes Cabazitaxel Efficacy and Intratumoral Accumulation in a Prostate Cancer Xenograft Model.Impact of Phosphoproteomics in the Era of Precision Medicine for Prostate Cancer.Is the detection rate of 18F-choline PET/CT influenced by androgen-deprivation therapy?Recent trends in the management of advanced prostate cancer
P2860
Q26740592-A6270E70-C108-4C8E-8576-FDEF4BCBE423Q28257270-615F67FC-673C-427D-B939-7FDEA90CCF04Q28646036-A4C63C78-A69E-4097-8BDA-4AC93C3B9945Q30276399-BC8EA903-8A6E-48BF-BFFD-9FCBDC3853DFQ30544584-7179B98E-EDAE-46B7-8776-F9C2064F9C20Q30643770-5B25CD09-F9B0-406A-8A99-E5C4D691E869Q33988757-1335A906-D756-44A9-932B-03407CB681F4Q34542337-B01205A6-10AC-4448-B724-0F07A7286437Q34555654-CBD8D69D-1EBE-4695-997E-CB97D6E4F202Q35238452-1035E403-0225-4C0B-9EC4-D944E892CDB6Q35431448-4B544A27-2C28-42FE-9560-3FF7310D511AQ35465076-122C6106-C86A-496D-BBF2-0CF583C70BD5Q35678429-63E97829-5B01-4CFB-8133-5DE33C49484AQ35864027-0133CCF9-9E8D-4632-A9EA-EFE6950FF286Q36149486-1B5615ED-297A-4511-8B74-D9F728982C0FQ36635865-47ADE8C3-80E1-4376-8AC8-A68BB5F9ACE8Q36682155-0981F8C8-3C4F-40CB-BE1B-B7714F71118DQ37537958-D0E64E4F-F362-4916-9C21-55AD98220CBAQ37573461-512F254E-ED88-4C5F-A71D-2DFCC4B4B50CQ38184622-A5F22456-63BC-4F4B-8523-C1CDA10131EDQ38413737-B4336A72-AAA0-445B-B8EA-A5D78E73E79BQ38734062-5B50A9F4-A3D1-41A6-B531-6A306F8776ABQ38815759-B5F47498-5351-4F00-BEE5-B6EEA409F1F3Q42585509-59E1ED8F-2B47-4674-9BA6-967538149226Q47825566-3AC21E3A-78A5-4F3A-804E-C20E4E7E7886Q47941645-744EC15D-191C-44FF-8777-AD3283934347Q49184042-8555F087-350C-49B5-BDF1-7C18AC197C6CQ49587940-C337C0EE-99F0-44D7-861F-D80CCBCDA72BQ50420907-C29860B0-E4E8-40DD-A6C0-00291E3BEE6BQ57817247-DFAA96AE-77C3-4AE5-A78C-536C91D511C8Q57821875-BDEA45A3-CF2F-465B-B91C-94619C1502AA
P2860
Bypass mechanisms of the androgen receptor pathway in therapy-resistant prostate cancer cell models.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Bypass mechanisms of the andro ...... t prostate cancer cell models.
@ast
Bypass mechanisms of the andro ...... t prostate cancer cell models.
@en
type
label
Bypass mechanisms of the andro ...... t prostate cancer cell models.
@ast
Bypass mechanisms of the andro ...... t prostate cancer cell models.
@en
prefLabel
Bypass mechanisms of the andro ...... t prostate cancer cell models.
@ast
Bypass mechanisms of the andro ...... t prostate cancer cell models.
@en
P2093
P2860
P4510
P1433
P1476
Bypass mechanisms of the andro ...... t prostate cancer cell models.
@en
P2093
Guido Jenster
Natasja F Dits
Rute B Marques
Sigrun Erkens-Schulze
Wytske M van Weerden
P2860
P304
P356
10.1371/JOURNAL.PONE.0013500
P407
P577
2010-10-19T00:00:00Z